Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes.
Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes. JCI Insight. 2020 07 09; 5(13).
View in:
PubMed
subject areas
Animals
Bone Marrow
Bone Marrow Cells
Cholesterol
Cholic Acids
Diabetes Mellitus, Experimental
Diabetes Mellitus, Type 2
Humans
Inflammation
Lipid Metabolism
Lipogenesis
Liver X Receptors
Mice
Retina
authors with profiles
Julia V Busik